← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lifesplice Pharma, Llc
Kennet Square Pa 19348, PA
$6,031,542
Total funding
7
Grants
Funding over time
peak $1.4M · FY2011–19$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$6,031,542 · 7
By mechanism
R44$2,758,329 · 1
R43$1,527,181 · 3
R21$1,072,800 · 2
U44$673,232 · 1
Investigators at Lifesplice Pharma, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Preclinical testing of the splice modulating oligonucleotide LSP-GR1$1,033,937
R44 · FY2015 · NS
Preclinical testing of the splice modulating oligonucleotide LSP-GR1$965,278
R44 · FY2016 · NS
Preclinical testing of the splice modulating oligonucleotide LSP-GR1$759,114
R44 · FY2014 · NS
Preclinical Evaluation of an SCN8A-directed Splice Modulating Oligonucleotide to Treat Dravet Syndrome$673,232
U44 · FY2019 · NS
Preclinical Testing of Splice Modulating Oligonucleotides Targeting SCN8A to Treat Dravet Syndrome$389,793
R43 · FY2018 · NS
Directing Splicing of SCN8A to Treat Dravet Syndrome$345,200
R21 · FY2015 · NS
Directing Splicing of SCN8A to Treat Dravet Syndrome$342,600
R21 · FY2014 · NS
Characterizing an AMPA Receptor Splice Modulator in Preventing Epileptogenesis$333,829
R43 · FY2011 · NS
Oligonucleotides that Modulate AMPA Receptor Alternative Splicing as Drug Candida$315,001
R43 · FY2011 · NS
Development of Splice Modulating Oligonucleotides Targeting RAGE as a Treatment for Alzheimer's Disease$245,000
R21 · FY2018 · AG
Preclinical Testing of Splice Modulating Oligonucleotides Targeting SCN8A to Treat Dravet Syndrome$185,688
R43 · FY2019 · NS
Characterizing an AMPA Receptor Splice Modulator in Preventing Epileptogenesis$160,906
R43 · FY2012 · NS
Oligonucleotides that Modulate AMPA Receptor Alternative Splicing as Drug Candida$141,964
R43 · FY2012 · NS
Development of Splice Modulating Oligonucleotides Targeting RAGE as a Treatment for Alzheimer's Disease$140,000
R21 · FY2019 · AG